Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
12–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with Fragile X Syndrome, who are at least moderately ill based on a Clinical Global Impression Severity score of at least 4 and have qualifying scores on the ABC-C and IQ test at Visit 1
You may not be if
Advanced, severe or unstable disease that may interfere with the study outcome evaluations
Cancer within the past 5 years, other than localized skin cancer
Current treatment with more than two psychoactive medications, excluding anti-epileptics
History of severe self-injurious behavior
Weigh less than 32 kg
Females who are sexually active
Clareo Health | Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome
